Press Releases
Philogen fornisce un aggiornamento sull’analisi ad interim prevista dallo studio di Fase III FIBROSARC che valuta Onfekafusp alfa (L19TNF) in pazienti con Sarcoma dei tessuti molli, in stato avanzato o metastatico, in prima linea.
FIBROSARC (NCT04650984) è uno studio di Fase III che valuta Onfekafusp alfa (L19TNF, noto anche come Fibromun) in combinazione con doxorubicina rispetto al solo utilizzo di doxorubicina come terapia di...
Read morePhilogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma
FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft...
Read morePhilogen introduce la piattaforma per il Whistleblowing (Direttiva EU 2019/1937)
Philogen S.p.A. adotta un processo di gestione delle segnalazioni di illeciti riguardanti la Società in linea con le previsioni normative introdotte dal D.lgs. 10 marzo 2023, n. 24 (c.d. “Decreto Whistleblowing”)....
Read moreUpcoming Events
Philogen to attend the Immunotherapy of Cancer Conference (ITOC) in Munich on March 21-23, 2024.
Prof. Dario Neri, PhD, (CEO and CSO of Philogen) is giving a presentation entitled “Immunocytokines”.
Follow the link here for more details
Philogen to attend the Immuno-Oncology Summit Europe in London on April 23-25, 2024.
Follow the link here for more details
Past Events
Philogen to attend the Italian Mid Cap Conference organised by Mediobanca on January 23-24, 2024
The Italian Midcap Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri and CFO Laura Baldi through a series of...
Read morePhilogen to attend the ESMO TAT congress in Paris on February 26-28, 2024
Prof. Dr. Giuseppe Curigliano, on behalf of Philogen, is giving a presentation about the Phase I DODEKA study on February 26th, entitled “Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19)...
Read moreFollowing the announcements of this morning, Philogen management is inviting you to a Webinar on December 5 at 15:00 GMT | 16:00 CET.
Please contact us at ir@philogen.com or follow the link below to register to the event:
https://us06web.zoom.us/webinar/register/1616473304091/WN_UQLuGhWHTtuozv1NvDMvMQ#/registration